BC
KALA icon

Bridgefront Capital’s KALA BIO KALA Stock Holding History

Bridgefront Capital’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19
Closed -$252K – 519
2021
Q2 		$252K Sell
19
-2
-10% -$31.4K 0.1% 415
2021
Q1 		$346K Buy
21
+10
+91% +$195K 0.11% 373
2020
Q4 		$192K Buy
+11
New +$207K 0.07% 522

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Bridgefront Capital's KALA Position: Q3 2021 in Review

Bridgefront Capital sold out of KALA BIO (KALA) in Q3 2021, closing a stake of 19 shares — an estimated $252K sold.

Bridgefront Capital first reported a position in KALA in Q4 2020 and held it in 3 quarters. The position peaked at $346K in Q1 2021. 99 funds tracked by Wall St. Rank hold KALA as of Q3 2021.

  • Bridgefront Capital reported no remaining KALA BIO position as of Q3 2021 after selling out during the quarter.
  • Bridgefront Capital sold 19 KALA BIO shares in Q3 2021, an estimated $252K.
  • Bridgefront Capital first reported a position in KALA BIO in Q4 2020 and held it in 3 quarters.
  • Bridgefront Capital's KALA BIO position peaked at $346K in Q1 2021.
  • 99 funds tracked by Wall St. Rank held KALA BIO as of Q3 2021.

Based on Bridgefront Capital's 13F filing for Q3 2021, filed 12 Nov 2021.